JP2020536109A5 - - Google Patents

Download PDF

Info

Publication number
JP2020536109A5
JP2020536109A5 JP2020519404A JP2020519404A JP2020536109A5 JP 2020536109 A5 JP2020536109 A5 JP 2020536109A5 JP 2020519404 A JP2020519404 A JP 2020519404A JP 2020519404 A JP2020519404 A JP 2020519404A JP 2020536109 A5 JP2020536109 A5 JP 2020536109A5
Authority
JP
Japan
Prior art keywords
antibody
amino acid
use according
seq
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020519404A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020536109A (ja
JP7274469B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2018/077217 external-priority patent/WO2019068907A1/en
Publication of JP2020536109A publication Critical patent/JP2020536109A/ja
Publication of JP2020536109A5 publication Critical patent/JP2020536109A5/ja
Application granted granted Critical
Publication of JP7274469B2 publication Critical patent/JP7274469B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020519404A 2017-10-06 2018-10-05 Ｃｄ３９／ｃｄ７３軸によるｔ細胞活性の回復 Active JP7274469B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762568812P 2017-10-06 2017-10-06
US62/568,812 2017-10-06
US201862686143P 2018-06-18 2018-06-18
US62/686,143 2018-06-18
PCT/EP2018/077217 WO2019068907A1 (en) 2017-10-06 2018-10-05 RESTORATION OF T CELL ACTIVITY BY AXIS CD39 / CD73

Publications (3)

Publication Number Publication Date
JP2020536109A JP2020536109A (ja) 2020-12-10
JP2020536109A5 true JP2020536109A5 (enExample) 2021-10-21
JP7274469B2 JP7274469B2 (ja) 2023-05-16

Family

ID=63799006

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020519404A Active JP7274469B2 (ja) 2017-10-06 2018-10-05 Ｃｄ３９／ｃｄ７３軸によるｔ細胞活性の回復

Country Status (11)

Country Link
US (2) US20190218308A1 (enExample)
EP (1) EP3692068B1 (enExample)
JP (1) JP7274469B2 (enExample)
KR (1) KR102710877B1 (enExample)
CN (1) CN111542539B (enExample)
AU (1) AU2018346447B2 (enExample)
BR (1) BR112020006809A2 (enExample)
CA (1) CA3074588A1 (enExample)
IL (1) IL273414A (enExample)
SG (1) SG11202002192QA (enExample)
WO (1) WO2019068907A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009095478A1 (en) 2008-01-31 2009-08-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies against human cd39 and use thereof for inhibiting t regulatory cells activity
GB2545676A (en) * 2015-12-21 2017-06-28 Dublin Inst Of Tech Prediction of therapeutic response using vibrational spectroscopy
KR102584011B1 (ko) 2017-03-16 2023-09-27 이나뜨 파르마 에스.에이. 암 치료를 위한 조성물 및 방법
SG11202000820PA (en) 2017-07-31 2020-02-27 Tizona Therapeutics Anti-cd39 antibodies, compositions comprising anti-cd39 antibodies and methods of using anti-cd39 antibodies
MX2020011588A (es) 2018-05-03 2020-12-07 Shanghai Epimab Biotherapeutics Co Ltd Anticuerpos de alta afinidad a pd-1 y lag-3 y proteinas de union bispecificas preparadas a partir de las mismas.
PT3807316T (pt) 2018-06-18 2024-07-29 Innate Pharma Composições e métodos para tratamento de cancro
MX2021012769A (es) 2019-04-23 2021-11-18 Innate Pharma Anticuerpos bloqueadores cd73.
CN113454121B (zh) * 2019-08-21 2022-03-08 和铂医药(上海)有限责任公司 抗cd73抗体及其应用
AU2020286284B2 (en) * 2019-08-27 2023-11-09 Elpiscience (Suzhou) Biopharma, Ltd. Novel anti-CD39 antibodies
CN110407941B (zh) * 2019-09-25 2020-01-14 上海岸迈生物科技有限公司 Cd39的高亲和力抗体及其用途
TW202118791A (zh) 2019-11-05 2021-05-16 大陸商北京加科思新藥研發有限公司 對cd39具有特異性的結合分子及其用途
WO2021127254A1 (en) * 2019-12-19 2021-06-24 Board Of Regents, The University Of Texas System Methods for treating glioblastoma
CN114106160A (zh) * 2020-08-28 2022-03-01 安源医药科技（上海）有限公司 抗SARS-CoV-2病毒单克隆抗体及应用
US20220133902A1 (en) * 2020-11-04 2022-05-05 Heidelberg Pharma Research Gmbh Composition Comprising a Combination of Immune Checkpoint Inhibitor and Antibody-Amatoxin Conjugate for Use in Cancer Therapy
TW202302638A (zh) * 2021-02-19 2023-01-16 美商健生生物科技公司 用於靶向調節性ｔ細胞以增強免疫監視之材料及方法
WO2022194988A2 (en) 2021-03-19 2022-09-22 Heidelberg Pharma Research Gmbh B-lymphocyte specific amatoxin antibody conjugates
KR20240156633A (ko) 2022-03-03 2024-10-30 아르커스 바이오사이언시즈 인코포레이티드 항-cd39 항체 및 이의 용도
CN119403837A (zh) * 2022-06-08 2025-02-07 上海华奥泰生物药业股份有限公司 Cd39/cd73双特异性抗原结合蛋白及其用途
EP4683650A2 (en) * 2023-03-21 2026-01-28 Beam Therapeutics Inc. Immunosuppressant-resistant modified allogeneic modified immune cells and methods for use thereof
CN120992939B (zh) * 2025-10-27 2025-12-26 苏州旭光科星抗体生物科技有限公司 一种可溶性cd39蛋白含量检测试剂盒及其应用

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5660827A (en) 1992-03-05 1997-08-26 Board Of Regents, The University Of Texas System Antibodies that bind to endoglin
US6387645B1 (en) * 1998-07-16 2002-05-14 Hyseq, Inc. Methods and materials relating to novel CD39-like polypeptides
ES2720160T3 (es) 2005-05-09 2019-07-18 Ono Pharmaceutical Co Anticuerpos monoclonales humanos contra muerte programada 1(PD-1) y métodos para tratar el cáncer usando anticuerpos dirigidos contra PD-1 solos o junto con otras sustancias inmunoterapéuticas
EA019344B1 (ru) 2005-07-01 2014-03-31 МЕДАРЕКС, Эл.Эл.Си. Человеческие моноклональные антитела против лиганда-1 запрограммированной гибели клеток (pd-l1) и их применения
WO2009014708A2 (en) 2007-07-23 2009-01-29 Cell Genesys, Inc. Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
WO2009095478A1 (en) * 2008-01-31 2009-08-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies against human cd39 and use thereof for inhibiting t regulatory cells activity
EP2242773B1 (en) 2008-02-11 2017-06-14 Cure Tech Ltd. Monoclonal antibodies for tumor treatment
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme PD-1 BINDING PROTEINS
HUE065752T2 (hu) 2008-12-09 2024-06-28 Hoffmann La Roche Anti-PD-L1 antitestek és felhasználásuk T-sejt funkció elõsegítésére
PT2504364T (pt) 2009-11-24 2017-11-14 Medimmune Ltd Agentes de ligação direcionados contra b7-h1
JP6072771B2 (ja) 2011-04-20 2017-02-01 メディミューン，エルエルシー Ｂ７−ｈ１およびｐｄ−１に結合する抗体およびその他の分子
EA026924B1 (ru) 2011-08-01 2017-05-31 Дженентек, Инк. Способы лечения рака с использованием антагонистов, связывающихся с осью pd-1, и ингибиторов mek
CA2862101A1 (en) * 2012-02-07 2013-08-15 Innate Pharma Mica binding agents
FR3011240A1 (fr) 2013-10-01 2015-04-03 Centre Nat Rech Scient Inhibiteurs de 5'-nucleotidases et leurs utilisations therapeutiques
ES2746805T3 (es) 2013-12-12 2020-03-06 Shanghai hengrui pharmaceutical co ltd Anticuerpo de PD-1, fragmento de unión a antígeno del mismo y aplicación médica del mismo
EP3134411B1 (en) 2014-04-25 2021-06-30 Boehringer Ingelheim International GmbH Purine derivatives as cd73 inhibitors for the treatment of cancer
KR102536786B1 (ko) * 2014-10-10 2023-05-26 이나뜨 파르마 에스.에이. Ｃｄ７３ 차단
MX385320B (es) 2014-11-10 2025-03-18 Medimmune Ltd Moléculas de unión específicas para grupo de diferenciación 73 (cd73) y usos de las mismas.
WO2016075176A1 (en) * 2014-11-11 2016-05-19 Medimmune Limited Therapeutic combinations comprising anti-cd73 antibodies and a2a receptor inhibitor and uses thereof
HUE050596T2 (hu) 2014-11-21 2020-12-28 Bristol Myers Squibb Co Antitestek CD73 ellen és azok felhasználásai
EP3259288A1 (en) 2015-02-20 2017-12-27 Innate Pharma Cd73 blockade
WO2017064043A1 (en) * 2015-10-12 2017-04-20 Innate Pharma Cd73 blocking agents
US20190153113A1 (en) 2015-11-23 2019-05-23 Innate Pharma Cd39 vascular isoform targeting agents
WO2017098421A1 (en) 2015-12-08 2017-06-15 Glaxosmithkline Intellectual Property Development Limited Benzothiadiazine compounds
CA3007646A1 (en) 2015-12-09 2017-06-15 Bioatla, Llc Humanized anti-cd73 antibodies
CA3151595A1 (en) 2016-01-08 2017-07-13 Arcus Biosciences, Inc. Modulators of 5'-nucleotidase, ecto and the use thereof
WO2017153952A1 (en) 2016-03-10 2017-09-14 Glaxosmithkline Intellectual Property Development Limited 5-sulfamoyl-2-hydroxybenzamide derivatives
CN110022881B (zh) 2016-11-18 2023-05-02 艾库斯生物科学有限公司 Cd73介导的免疫抑制的抑制剂
KR102584011B1 (ko) * 2017-03-16 2023-09-27 이나뜨 파르마 에스.에이. 암 치료를 위한 조성물 및 방법
SG11202002195YA (en) * 2017-11-15 2020-04-29 Innate Pharma Potentiating the effect of atp release
MX2021012769A (es) * 2019-04-23 2021-11-18 Innate Pharma Anticuerpos bloqueadores cd73.
US12098212B2 (en) * 2019-08-12 2024-09-24 Purinomia Biotech, Inc. Methods and compositions for promoting and potentiating T-cell mediated immune responses through ADCC targeting of CD39 expressing cells

Similar Documents

Publication Publication Date Title
JP2020536109A5 (enExample)
JP7664357B2 (ja) 抗ｍｅｔ抗体、ｍｅｔに結合する二重特異性抗原結合分子およびその使用方法
JP2020513809A5 (enExample)
JP7288920B2 (ja) シンデカン－２のモジュレーターとその使用
TWI712423B (zh) 抗ｔｒｏｐ２抗體-藥物結合物之製造方法
JP2022093564A5 (enExample)
CN109563170B (zh) 抗gitr抗体及其用途
CN110799540B (zh) 多特异性抗体及其制备和使用方法
AU2024202552A1 (en) Neutralization of inhibitory pathways in lymphocytes
CN113366016B (zh) 抗人白细胞介素5(il-5)单克隆抗体及其应用
NZ713461A (en) Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer
RU2017107559A (ru) Лечение раковых заболеваний с применением анти-nkg2a средств
RU2019111722A (ru) Антитела против siglec-15 и способы их применения
JP2017535257A5 (enExample)
RU2018119296A (ru) Конъюгаты антитела, содержащие агонисты толл-подобного рецептора
JP2009505676A5 (enExample)
JP2018521691A5 (enExample)
RU2011110405A (ru) Агенты, связывающие рецептор frizzled и их применение
RU2014101669A (ru) Агенты, связывающие белки r-спондины (rspo), и способы их применения
JP2018534933A5 (enExample)
RU2012137498A (ru) Фармацевтическая композиция для лечения и/или профилактики рака
JP2015509962A5 (enExample)
JP2010535713A5 (enExample)
JP2021502980A5 (enExample)
HRP20220918T1 (hr) Anti-transtiretinska antitijela